{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:42Z","timestamp":1793726082177,"version":"4.6.1"},"reference-count":177,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Invasive aspergillosis is an opportunistic infection caused by the Aspergillus species. It is a significant cause of morbidity and mortality in susceptible populations, including recipients of bone marrow and solid organ transplants. Azole antifungals have remained the first-line treatment for invasive aspergillosis for a long time; however, the advance of azole resistance in Aspergillus fumigatus, driven predominantly by extensive commercial and agricultural use of azole fungicides and environmental exposure of susceptible populations to the resistant strains, renders the traditional therapeutic approaches less effective and results in further increase in mortality. The epidemiology, molecular mechanisms of azole resistance, diagnostic approaches, and clinical implications of azole resistance in Aspergillus fumigatus sensu stricto will be discussed in this article (for ease of comprehension, the rest of this article will refer to A. fumigatus sensu stricto as A. fumigatus).<\/jats:p>","DOI":"10.3390\/jof11100731","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:34:08Z","timestamp":1760114048000},"page":"731","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Azole-Resistant Aspergillus fumigatus: Epidemiology, Diagnosis, and Treatment Considerations"],"prefix":"10.3390","volume":"11","author":[{"given":"Anna","family":"Zubovskaia","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Wellstar MCG, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC), European Chemicals Agency (ECHA), European Environment Agency (EEA), European Medicines Agency (EMA), and European Commission\u2019s Joint Research Centre (JRC) (2025). Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant Aspergillus spp. EFSA J., 23, e9200.","DOI":"10.2903\/j.efsa.2025.9200"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"De Francesco, M.A. (2023). Drug-Resistant Aspergillus spp.: A Literature Review of Its Resistance Mechanisms and Its Prevalence in Europe. Pathogens, 12.","DOI":"10.3390\/pathogens12111305"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in Aspergillus fumigatus: Recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zubovskaia, A., and Vazquez, J.A. (2025). Invasive Aspergillosis in the Intensive Care Unit. J. Fungi, 11.","DOI":"10.3390\/jof11010070"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of Direct Healthcare Costs of Fungal Diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/13693786.2012.738312","article-title":"Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults","volume":"51","author":"Denning","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_7","first-page":"673","article-title":"Chronic Pulmonary Aspergillosis: A Brief Review","volume":"94","author":"Zarif","year":"2021","journal-title":"Yale J. Biol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Arendrup, M.C., Mavridou, E., Mortensen, K.L., Snelders, E., Frimodt-M\u00f8ller, N., Khan, H., Melchers, W.J., and Verweij, P.E. (2010). Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010080"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Burks, C., Darby, A., G\u00f3mez Londo\u00f1o, L., Momany, M., and Brewer, M.T. (2021). Azole-resistant Aspergillus fumigatus in the environment: Identifying key reservoirs and hotspots of antifungal resistance. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009711"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Kathuria, S., Xu, J., and Meis, J.F. (2013). Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog., 9, Erratum in PLoS Pathog. 2013, 9, e1003633. https:\/\/doi.org\/10.1371\/annotation\/4ffcf1da-b180-4149-834c-9c723c5dbf9b.","DOI":"10.1371\/journal.ppat.1003633"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, J., van den Heuvel, J., Debets, A.J.M., Verweij, P.E., Melchers, W.J.G., Zwaan, B.J., and Schoustra, S.E. (2017). Evolution of cross-resistance to medical triazoles in Aspergillus fumigatus through selection pressure of environmental fungicides. Proc. Biol. Sci., 284.","DOI":"10.1098\/rspb.2017.0635"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/cid\/cix297","article-title":"Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation with Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999\u20132015","volume":"65","author":"Heo","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41564-025-02055-y","article-title":"Evolution of antifungal resistance in the environment","volume":"10","author":"Rhodes","year":"2025","journal-title":"Nat. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S795","DOI":"10.1093\/ofid\/ofaa439.1778","article-title":"1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY)\u2014A multicenter study","volume":"7","author":"Seidel","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Carvalhaes, C.G., Rhomberg, P.R., Desphande, L.M., and Castanheira, M. (2024). Trends in the activity of mold-active azole agents against Aspergillus fumigatus clinical isolates with and without cyp51 alterations from Europe and North America (2017\u20132021). J. Clin. Microbiol., 62.","DOI":"10.1128\/jcm.01141-23"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101114","DOI":"10.1016\/j.lanmic.2025.101114","article-title":"Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: A genomic and phenotypic study","volume":"6","author":"Song","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dkz144","article-title":"One-year prospective survey of azole resistance in Aspergillus fumigatus at a French cystic fibrosis reference center: Prevalence and mechanisms of resistance","volume":"74","author":"Lavergne","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11046-025-00941-x","article-title":"Trends of Azole-Resistant Aspergillus fumigatus Susceptibility over 12 Years from a German ECMM Excellence Center","volume":"190","author":"Verhasselt","year":"2025","journal-title":"Mycopathologia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/myc.13426","article-title":"Azole resistance in Aspergillus fumigatus. The first 2-year\u2019s Data from the Danish National Surveillance Study, 2018\u20132020","volume":"65","author":"Risum","year":"2022","journal-title":"Mycoses"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1170.e1","DOI":"10.1016\/j.cmi.2020.09.042","article-title":"Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain","volume":"27","author":"Escribano","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13719","DOI":"10.1111\/myc.13719","article-title":"Distribution of Aspergillus species and prevalence of azole resistance in clinical and environmental samples from a Spanish hospital during a three-year study period","volume":"67","author":"Lucio","year":"2024","journal-title":"Mycoses"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3201\/eid2009.140142","article-title":"Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011\u20132013","volume":"20","author":"Pham","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e02240-17","DOI":"10.1128\/AAC.02240-17","article-title":"Detection of TR34\/L98H CYP51A Mutation through Passive Surveillance for Azole-Resistant Aspergillus fumigatus in the United States from 2015 to 2017","volume":"62","author":"Berkow","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Etienne, K.A., Berkow, E.L., Gade, L., Nunnally, N., Lockhart, S.R., Beer, K., Jordan, I.K., Rishishwar, L., and Litvintseva, A.P. (2021). Genomic Diversity of Azole-Resistant Aspergillus fumigatus in the United States. mBio, 12.","DOI":"10.1128\/mBio.01803-21"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Celia-Sanchez, B.N., Mangum, B., G\u00f3mez Londo\u00f1o, L.F., Wang, C., Shuman, B., Brewer, M.T., and Momany, M. (2024). Pan-azole- and multi-fungicide-resistant Aspergillus fumigatus is widespread in the United States. Appl. Environ. Microbiol., 90.","DOI":"10.1128\/aem.01782-23"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wang, C., Miller, N., Vines, D., Severns, P.M., Momany, M., and Brewer, M.T. (2024). Azole resistance mechanisms and population structure of the human pathogen Aspergillus fumigatus on retail plant products. Appl. Environ. Microbiol., 90.","DOI":"10.1128\/aem.02056-23"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3201\/eid2401.170971","article-title":"Recognition of Azole-Resistant Aspergillosis by Physicians Specializing in Infectious Diseases, United States","volume":"24","author":"Walker","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e02264-17","DOI":"10.1128\/AAC.02264-17","article-title":"Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India","volume":"62","author":"Dabas","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Sharma, C., Kathuria, S., Hagen, F., and Meis, J.F. (2015). Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00428"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jac\/dkr443","article-title":"Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR\/L98H mutations in the cyp51A gene in India","volume":"67","author":"Chowdhary","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kang, Y., Ma, W., Li, Q., Wang, P., and Jia, W. (2025). Epidemiology, antifungal susceptibility and biological characteristics of clinical Aspergillus fumigatus in a tertiary hospital. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-00187-z"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00066-21","DOI":"10.1128\/mSphere.00066-21","article-title":"Extensive Genetic Diversity and Widespread Azole Resistance in Greenhouse Populations of Aspergillus fumigatus in Yunnan, China","volume":"6","author":"Zhou","year":"2021","journal-title":"mSphere"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1128\/AAC.01005-16","article-title":"Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental Aspergillus fumigatus Isolates from China","volume":"60","author":"Chen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e01594-24","DOI":"10.1128\/spectrum.01594-24","article-title":"Unveiling environmental transmission risks: Comparative analysis of azole resistance in Aspergillus fumigatus clinical and environmental isolates from Yunnan, China","volume":"12","author":"Gong","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1111\/1462-2920.15660","article-title":"Azole-resistant Aspergillus fumigatus is highly prevalent in the environment of Vietnam, with marked variability by land use type","volume":"23","author":"Duong","year":"2021","journal-title":"Environ. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12281-023-00459-z","article-title":"Invasive Aspergillosis and the Impact of Azole-resistance","volume":"17","author":"Bosetti","year":"2023","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12281-021-00418-6","article-title":"Emergence of Triazole Resistance in Aspergillus spp. in Latin America","volume":"15","author":"Macedo","year":"2021","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Resendiz-Sharpe, A., Dewaele, K., Merckx, R., Bustamante, B., Vega-Gomez, M.C., Rolon, M., Jacobs, J., Verweij, P.E., Maertens, J., and Lagrou, K. (2021). Triazole-Resistance in Environmental Aspergillus fumigatus in Latin American and African Countries. J. Fungi, 7.","DOI":"10.3390\/jof7040292"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"myac059","DOI":"10.1093\/mmy\/myac059","article-title":"Triazole resistance in Aspergillus fumigatus isolates in Africa: A systematic review","volume":"60","author":"Amona","year":"2022","journal-title":"Med. Mycol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00608-17","DOI":"10.1128\/AAC.00608-17","article-title":"Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients","volume":"61","author":"Negri","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/mmy\/myz032","article-title":"Azole resistance among clinical isolates of Aspergillus fumigatus in Lima-Peru","volume":"58","author":"Bustamante","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/jac\/dky187","article-title":"Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates","volume":"73","author":"Talbot","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_46","first-page":"100888","article-title":"Invasive aspergillosis in adult patients in Australia and New Zealand: 2017\u20132020","volume":"40","author":"Tio","year":"2023","journal-title":"Lancet Reg. Health West Pac."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41564-022-01091-2","article-title":"Population genomics confirms acquisition of drug-resistant Aspergillus fumigatus infection by humans from the environment","volume":"7","author":"Rhodes","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Monk, B.C., Sagatova, A.A., Hosseini, P., Ruma, Y.N., Wilson, R.K., and Keniya, M.V. (2020). Fungal Lanosterol 14\u03b1-demethylase: A target for next-generation antifungal design. Biochim. Biophys. Acta Proteins Proteom., 1868.","DOI":"10.1016\/j.bbapap.2019.02.008"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"105807","DOI":"10.1016\/j.ijantimicag.2019.09.011","article-title":"Azole resistance mechanisms in Aspergillus: Update and recent advances","volume":"55","author":"Guarro","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e0125221","DOI":"10.1128\/AAC.01252-21","article-title":"Point Mutation or Overexpression of Aspergillus fumigatus cyp51B, Encoding Lanosterol 14\u03b1-Sterol Demethylase, Leads to Triazole Resistance","volume":"65","author":"Handelman","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/dky517","article-title":"Emerging threat of triazole-resistant Aspergillus fumigatus","volume":"74","author":"Rybak","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e00735-20","DOI":"10.1128\/AAC.00735-20","article-title":"Aspergillus fumigatus Cyp51A and Cyp51B Proteins Are Compensatory in Function and Localize Differentially in Response to Antifungals and Cell Wall Inhibitors","volume":"64","author":"Roundtree","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1111\/1462-2920.15274","article-title":"Mechanisms of triazole resistance in Aspergillus fumigatus","volume":"22","author":"Nywening","year":"2020","journal-title":"Environ. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"myae055","DOI":"10.1093\/mmy\/myae055","article-title":"Detection of pan-azole resistant Aspergillus fumigatus in horticulture and a composting facility in Belgium","volume":"62","author":"Debergh","year":"2024","journal-title":"Med. Mycol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.fgb.2011.08.002","article-title":"The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance","volume":"48","author":"Snelders","year":"2011","journal-title":"Fungal Genet. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.fgb.2015.06.001","article-title":"Genotype-phenotype complexity of the TR46\/Y121F\/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus","volume":"82","author":"Snelders","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles","volume":"57","author":"Camps","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e00791-17","DOI":"10.1128\/mBio.00791-17","article-title":"A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence","volume":"8","author":"Zhang","year":"2017","journal-title":"mBio"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Buil, J.B., Zoll, J., Verweij, P.E., and Melchers, W.J.G. (2018). Molecular Detection of Azole-Resistant Aspergillus fumigatus in Clinical Samples. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00515"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13693780802545600","article-title":"Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery","volume":"47","author":"Hodiamont","year":"2009","journal-title":"Med. Mycol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Snelders, E., Camps, S.M., Karawajczyk, A., Schaftenaar, G., Kema, G.H., van der Lee, H.A., Klaassen, C.H., Melchers, W.J., and Verweij, P.E. (2012). Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031801"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Meis, J.F., Chowdhary, A., Rhodes, J.L., Fisher, M.C., and Verweij, P.E. (2016). Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos. Trans. R Soc. Lond. B Biol. Sci., 371.","DOI":"10.1098\/rstb.2015.0460"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"jkab427","DOI":"10.1093\/g3journal\/jkab427","article-title":"Evidence for the agricultural origin of resistance to multiple antimicrobials in Aspergillus fumigatus, a fungal pathogen of humans","volume":"12","author":"Kang","year":"2022","journal-title":"G3"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3201\/eid2503.180297","article-title":"In Vivo Selection of a Unique Tandem Repeat Mediated Azole Resistance Mechanism (TR120) in Aspergillus fumigatus cyp51A, Denmark","volume":"25","author":"Hare","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Pontes, L., Arai, T., Gualtieri Beraquet, C.A., Giordano, A.L.P.L., Reichert-Lima, F., da Luz, E.A., Fernanda de S\u00e1, C., Ortolan Levy, L., Tararam, C.A., and Watanabe, A. (2024). Uncovering a Novel cyp51A Mutation and Antifungal Resistance in Aspergillus fumigatus through Culture Collection Screening. J. Fungi, 10.","DOI":"10.3390\/jof10020122"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3201\/eid2507.181625","article-title":"Environmental Hotspots for Azole Resistance Selection of Aspergillus fumigatus, the Netherlands","volume":"25","author":"Schoustra","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1128\/JCM.00329-12","article-title":"Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis","volume":"50","author":"Pelaez","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Gonzalez-Jimenez, I., Lucio, J., Men\u00e9ndez-Fraga, M.D., Mellado, E., and Pel\u00e1ez, T. (2021). Hospital Environment as a Source of Azole-Resistant Aspergillus fumigatus Strains with TR34\/L98H and G448S Cyp51A Mutations. J. Fungi, 7.","DOI":"10.3390\/jof7010022"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jac\/dks451","article-title":"High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates","volume":"68","author":"Buied","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gonzalez-Jimenez, I., Lucio, J., Amich, J., Cuesta, I., Sanchez Arroyo, R., Alcazar-Fuoli, L., and Mellado, E. (2020). A Cyp51B Mutation Contributes to Azole Resistance in Aspergillus fumigatus. J. Fungi, 6.","DOI":"10.3390\/jof6040315"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/jac\/dkq279","article-title":"Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009","volume":"65","author":"Bueid","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s40588-015-0015-1","article-title":"Update on Antifungal Drug Resistance","volume":"2","author":"Perlin","year":"2015","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100915","DOI":"10.1016\/j.mycmed.2019.100915","article-title":"Exploring the molecular mechanism of azole resistance in Aspergillus fumigatus","volume":"30","author":"Chen","year":"2020","journal-title":"J. Mycol. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","article-title":"The global problem of antifungal resistance: Prevalence, mechanisms, and management","volume":"17","author":"Perlin","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gsaller, F., Hortschansky, P., Furukawa, T., Carr, P.D., Rash, B., Capilla, J., M\u00fcller, C., Bracher, F., Bowyer, P., and Haas, H. (2016). Sterol Biosynthesis and Azole Tolerance Is Governed by the Opposing Actions of SrbA and the CCAAT Binding Complex. PLoS Pathog., 12, Erratum in PLoS Pathog. 2016, 12, e1006106. https:\/\/doi.org\/10.1371\/journal.ppat.1006106.","DOI":"10.1371\/journal.ppat.1006106"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Camps, S.M., Dutilh, B.E., Arendrup, M.C., Rijs, A.J., Snelders, E., Huynen, M.A., Verweij, P.E., and Melchers, W.J. (2012). Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050034"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e02563-18","DOI":"10.1128\/mBio.02563-18","article-title":"AtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus","volume":"10","author":"Paul","year":"2019","journal-title":"mBio"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Hagiwara, D., Miura, D., Shimizu, K., Paul, S., Ohba, A., Gonoi, T., Watanabe, A., Kamei, K., Shintani, T., and Moye-Rowley, W.S. (2017). A Novel Zn2-Cys6 Transcription Factor AtrR Plays a Key Role in an Azole Resistance Mechanism of Aspergillus fumigatus by Co-regulating cyp51A and cdr1B Expressions. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006096"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41467-019-14191-1","article-title":"The negative cofactor 2 complex is a key regulator of drug resistance in Aspergillus fumigatus","volume":"11","author":"Furukawa","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/mmy\/myw005","article-title":"Identification of Aspergillus fumigatus multidrug transporter genes and their potential involvement in antifungal resistance","volume":"54","author":"Meneau","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkt075","article-title":"The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus","volume":"68","author":"Fraczek","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e02748-16","DOI":"10.1128\/AAC.02748-16","article-title":"Contributions of both ATP-Binding Cassette Transporter and Cyp51A Proteins Are Essential for Azole Resistance in Aspergillus fumigatus","volume":"61","author":"Paul","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Sturm, L., Gei\u00dfel, B., Martin, R., and Wagener, J. (2020). Differentially Regulated Transcription Factors and ABC Transporters in a Mitochondrial Dynamics Mutant Can Alter Azole Susceptibility of Aspergillus fumigatus. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01017"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e00437-19","DOI":"10.1128\/mBio.00437-19","article-title":"Mutations in hmg1, Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus","volume":"10","author":"Rybak","year":"2019","journal-title":"mBio"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3201\/eid2410.180730","article-title":"Non-cyp51A Azole-Resistant Aspergillus fumigatus Isolates with Mutation in HMG-CoA Reductase","volume":"24","author":"Hagiwara","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e02101-16","DOI":"10.1128\/AAC.02101-16","article-title":"Screening and Characterization of a Non-cyp51A Mutation in an Aspergillus fumigatus cox10 Strain Conferring Azole Resistance","volume":"61","author":"Wei","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1093\/mmy\/myy075","article-title":"Calcium signaling pathway is involved in non-CYP51 azole resistance in Aspergillus fumigatus","volume":"57","author":"Li","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.fgb.2014.12.005","article-title":"Calcium signaling mediates antifungal activity of triazole drugs in the Aspergilli","volume":"81","author":"Liu","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jam.12576","article-title":"In vitro evaluation of combination of polyenes with EDTA against Aspergillus spp. by different methods (FICI and CI Model)","volume":"117","author":"Ruhil","year":"2014","journal-title":"J. Appl. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Liu, S., Le Mauff, F., Sheppard, D.C., and Zhang, S. (2022). Filamentous fungal biofilms: Conserved and unique aspects of extracellular matrix composition, mechanisms of drug resistance and regulatory networks in Aspergillus fumigatus. NPJ Biofilms Microbiomes, 8.","DOI":"10.1038\/s41522-022-00347-3"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Barker, B.M., Kroll, K., V\u00f6disch, M., Mazurie, A., Kniemeyer, O., and Cramer, R.A. (2012). Transcriptomic and proteomic analyses of the Aspergillus fumigatus hypoxia response using an oxygen-controlled fermenter. BMC Genom., 13.","DOI":"10.1186\/1471-2164-13-62"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lucio, J., Gonzalez-Jimenez, I., Roldan, A., Amich, J., Alcazar-Fuoli, L., and Mellado, E. (2024). Importance of the Aspergillus fumigatus Mismatch Repair Protein Msh6 in Antifungal Resistance Development. J. Fungi, 10.","DOI":"10.3390\/jof10030210"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10654","DOI":"10.1038\/s41467-024-54568-5","article-title":"Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance","volume":"15","author":"Bottery","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Bowyer, P., Weaver, D., Qi, T., Chown, H., Fraczek, M., Lebedinec, R., Dineen, L., Valero, C., van Rhijn, N., and Furukawa, T. (2025). Genome-wide discovery and phenotyping of non-coding transcripts in A. fumigatus reveals lncRNAs with a role in antifungal drug sensitivity. Res. Sq.","DOI":"10.21203\/rs.3.rs-6048166\/v1"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e00168-17","DOI":"10.1128\/AAC.00168-17","article-title":"Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method","volume":"61","author":"Mello","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2025, September 27). Breakpoint Tables for Interpretation of MICs for Antifungal Agents, Version 11.0. Available online: http:\/\/www.eucast.org\/astoffungi\/clinicalbreakpointsforantifungals\/."},{"key":"ref_102","unstructured":"Wiederhold, N.P., Andes, D., Borman, A.M., Dufresne, P.J., Lockhart, S.R., and Procop, G.W. (2024). Voriconazole Breakpoints for Aspergillus fumigatus, CLSI. [1st ed.]. CLSI rationale document FR01."},{"key":"ref_103","unstructured":"Wiederhold, N.P., Andes, D., Borman, A.M., Dufresne, P.J., Lockhart, S., and Procop, G. (2025). Isavuconazole Breakpoints for Aspergillus fumigatus, CLSI. [1st ed.]. CLSI rationale document FR02."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/myc.13347","article-title":"A simple high-volume culture technique-Good substitute for polymerase chain reaction for the detection of Aspergillus species in bronchoalveolar lavage samples","volume":"65","author":"Subhagan","year":"2022","journal-title":"Mycoses"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2019.11.019","article-title":"High-volume culture and quantitative real-time PCR for the detection of Aspergillus in sputum","volume":"26","author":"Vergidis","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cll.2024.10.009","article-title":"Molecular Diagnostics for Invasive Molds: From Lab to Bedside","volume":"45","author":"Hannaford","year":"2025","journal-title":"Clin. Lab. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Garnaud, C., Brenier-Pinchart, M.P., Thi\u00e9baut-Bertrand, A., Saint-Raymond, C., Camara, B., Hamidfar, R., Cognet, O., Maubon, D., and Cornet, M. (2016). Direct Molecular Diagnosis of Aspergillosis and CYP51A Profiling from Respiratory Samples of French Patients. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01164"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e00604-19","DOI":"10.1128\/JCM.00604-19","article-title":"A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of Aspergillus fumigatus, Even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells","volume":"57","author":"Wang","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12281-019-00342-w","article-title":"(New) Methods for Detection of Aspergillus fumigatus Resistance in Clinical Samples","volume":"13","author":"Jenks","year":"2019","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_110","first-page":"402","article-title":"Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is Aspergillus?","volume":"55","author":"Morton","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Rath, P.M., and Steinmann, J. (2018). Overview of Commercially Available PCR Assays for the Detection of Aspergillus spp. DNA in Patient Samples. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00740"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/jac\/dkw323","article-title":"PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: A multicentre validation of the AsperGenius assay\u00ae in 201 patients with haematological disease suspected for invasive aspergillosis","volume":"71","author":"Chong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/jac\/dkx262","article-title":"Detection of azole-susceptible and azole-resistant Aspergillus coinfection by cyp51A PCR amplicon melting curve analysis","volume":"72","author":"Schauwvlieghe","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/JCM.00411-17","article-title":"Analytical and Clinical Evaluation of the PathoNostics AsperGenius Assay for Detection of Invasive Aspergillosis and Resistance to Azole Antifungal Drugs Directly from Plasma Samples","volume":"55","author":"White","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Scharmann, U., Kirchhoff, L., Hain, A., Buer, J., Koldehoff, M., Steinmann, J., and Rath, P.M. (2021). Evaluation of Three Commercial PCR Assays for the Detection of Azole-Resistant Aspergillus fumigatus from Respiratory Samples of Immunocompromised Patients. J. Fungi, 7.","DOI":"10.3390\/jof7020132"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/cid\/ciad141","article-title":"Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study","volume":"77","author":"Huygens","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/JCM.00520-17","article-title":"Culture-Based Methods and Molecular Tools for Azole-Resistant Aspergillus fumigatus Detection in a Belgian University Hospital","volume":"55","author":"Montesinos","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Postina, P., Skladny, J., Boch, T., Cornely, O.A., Hamprecht, A., Rath, P.M., Steinmann, J., Bader, O., Miethke, T., and Dietz, A. (2018). Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00555"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1128\/JCM.01032-17","article-title":"Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit","volume":"55","author":"Dannaoui","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/mmy\/myz002","article-title":"Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: The need for a combined use with galactomannan","volume":"57","author":"Mikulska","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"van der Torre, M.H., Novak-Frazer, L., and Rautemaa-Richardson, R. (2020). Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing. J. Fungi, 6.","DOI":"10.3390\/jof6010012"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cmi.2021.06.005","article-title":"Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry","volume":"28","author":"Zvezdanova","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ara\u00fajo, E., Gusm\u00e3o, N., Silva, T., Pape, P.L., and Lima-Neto, R.G. (2022). MALDI-TOF MS-based evaluation for azole-susceptibility testing of Aspergillus fumigatus over reference broth microdilution method. Res. Sq.","DOI":"10.21203\/rs.3.rs-1386445\/v1"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Yamashita, K., Yaguchi, T., Miwa, E., Kiyuna, T., Shima, K., Ito, J., Arai, T., Watanabe, A., and Ban, S. (2022). A MALDI-TOF MS-based discriminant model to distinguish azole-resistant Aspergillus fumigatus strains. Res. Sq.","DOI":"10.21203\/rs.3.rs-2053045\/v1"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Pu\u00e9rtolas-Balint, F., Rossen, J.W.A., Oliveira Dos Santos, C., Chlebowicz, M.M.A., Raangs, E.C., van Putten, M.L., Sola-Campoy, P.J., Han, L., Schmidt, M., and Garc\u00eda-Cobos, S. (2019). Revealing the Virulence Potential of Clinical and Environmental Aspergillus fumigatus Isolates Using Whole-Genome Sequencing. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01970"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Brackin, A.P., Leitao, R., Rhodes, J., Chaudhry, Z., Connell, D., Hemmings, S., Shelton, J.M.G., Fisher, M.C., Armstrong-James, D., and Shah, A. (2025). Genomic epidemiology links azole-resistant Aspergillus fumigatus hospital bioaerosols to chronic respiratory aspergillosis. medRxiv.","DOI":"10.1101\/2025.07.04.25330042"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Tashiro, M., Nakano, Y., Shirahige, T., Kakiuchi, S., Fujita, A., Tanaka, T., Takazono, T., and Izumikawa, K. (2025). Comprehensive Review of Environmental Surveillance for Azole-Resistant Aspergillus fumigatus: A Practical Roadmap for Hospital Clinicians and Infection Control Teams. J. Fungi, 11.","DOI":"10.3390\/jof11020096"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Caldera, J.R., Dayo, A., Wiederhold, N., and Yang, S. (2025). Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in Aspergillus fumigatus. J. Clin. Microbiol., 63.","DOI":"10.1128\/jcm.00291-25"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"Douglas","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_131","unstructured":"Kullber, B.J., Blijlevens, N.M.A., Jannsen, J.J.W.M., Meis, J.F.G., Verweij, P.E., Oude Lashof, A.M.L., van de Veerdonk, F.L., Rijnders, B.J., Br\u00fcggemann, R.J.M., and vd Werf, T.S. (2025, September 27). SWAB Guidelines for the Management of Invasive Fungal Infections. Revised Version. Released 14 Dec 2017. Available online: https:\/\/swab.nl\/nl\/exec\/file\/download\/86."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drup.2014.06.001","article-title":"The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside","volume":"17","author":"Seyedmousavi","year":"2014","journal-title":"Drug Resist. Updates"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.diagmicrobio.2012.02.003","article-title":"In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus","volume":"73","author":"Wu","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1128\/AAC.01111-12","article-title":"Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis","volume":"56","author":"Jeans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkw276","article-title":"Dose optimization of voriconazole\/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic\/pharmacodynamic model and response surface analysis: Clinical implications for azole-resistant aspergillosis","volume":"71","author":"Siopi","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkaa185","article-title":"In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates","volume":"75","author":"Buil","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/myc.13028","article-title":"High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections","volume":"63","author":"Schauwvlieghe","year":"2020","journal-title":"Mycoses"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Vanhoffelen, E., Van Win, T., Van Braeckel, E., Res\u00e9ndiz-Sharpe, A., Cammue, B.P.A., Lagrou, K., Thevissen, K., and Vande Velde, G. (2025). Combinations of posaconazole and tacrolimus are effective against infections with azole-resistant Aspergillus fumigatus. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1550457"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dku364","article-title":"Azole, polyene and echinocandin MIC distributions for wild-type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands","volume":"70","author":"Rijs","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive Aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e01618-20","DOI":"10.1128\/AAC.01618-20","article-title":"Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic\/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?","volume":"65","author":"Siopi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/IDR.S372546","article-title":"Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations","volume":"16","author":"Egger","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Rivero-Menendez, O., Soto-Debran, J.C., Cuenca-Estrella, M., and Alastruey-Izquierdo, A. (2021). In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies. J. Fungi, 7.","DOI":"10.3390\/jof7030232"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e02429-19","DOI":"10.1128\/AAC.02429-19","article-title":"Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1\u21923)-\u03b2-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e00244-18","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","unstructured":"(2025, July 29). Clinical Drug Experience Knowledgebase: Trial NCT03059992. Available online: https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT03059992\/."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1291.e7","DOI":"10.1016\/j.cmi.2022.05.013","article-title":"In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: Activity is retained against isolates showing resistance to azoles and\/or amphotericin B","volume":"28","author":"Escribano","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Feuss, A., Bougnoux, M.E., and Dannaoui, E. (2024). The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies. J. Fungi, 10.","DOI":"10.3390\/jof10050345"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Vanbiervliet, Y., Van Nieuwenhuyse, T., Aerts, R., Lagrou, K., Spriet, I., and Maertens, J. (2024). Review of the novel antifungal drug olorofim (F901318). BMC Infect. Dis., 24, Erratum in BMC Infect. Dis. 2024, 24, 1395. https:\/\/doi.org\/10.1186\/s12879-024-10295-2.","DOI":"10.1186\/s12879-024-10143-3"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"du Pr\u00e9, S., Birch, M., Law, D., Beckmann, N., Sibley, G.E.M., Bromley, M.J., Read, N.D., and Oliver, J.D. (2020). The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus. J. Fungi, 6.","DOI":"10.3390\/jof6020047"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e00231-18","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus","volume":"62","author":"Beckmann","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Maertens, J.A., Thompson, G.R., Spec, A., Donovan, F.M., Hammond, S.P., Bruns, A.H.W., Rahav, G., Shoham, S., Johnson, R., and Rijnders, B. (2025). Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: A single-arm, open-label, phase 2b study. Lancet Infect. Dis., Epub ahead of print.","DOI":"10.1016\/S1473-3099(25)00224-5"},{"key":"ref_158","first-page":"29","article-title":"Aspergillus fumigatus strains that evolve resistance to the agrochemical fungicide ipflufenoquin in vitro are also resistant to olorofim","volume":"9","author":"Storer","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"van Rhijn, N., Hemmings, S., Storer, I.S.R., Valero, C., Bin Shuraym, H., Goldman, G.H., Gsaller, F., Amich, J., and Bromley, M.J. (2022). Antagonism of the Azoles to Olorofim and Cross-Resistance Are Governed by Linked Transcriptional Networks in Aspergillus fumigatus. mBio, 13.","DOI":"10.1128\/mbio.02215-22"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/jac\/dkac062","article-title":"Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim","volume":"77","author":"Kirchhoff","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11046-023-00727-z","article-title":"Treatment of Invasive Aspergillosis: How It\u2019s Going, Where It\u2019s Heading","volume":"188","author":"Boyer","year":"2023","journal-title":"Mycopathologia"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cmi.2024.03.006","article-title":"New treatment options for critically important WHO fungal priority pathogens","volume":"31","author":"Kriegl","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Hodges, M.R., Tawadrous, M., Cornely, O.A., Thompson, G.R., Slavin, M.A., Maertens, J.A., Dadwal, S.S., Rahav, G., Hazel, S., and Almas, M. (2025). Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clin. Infect. Dis., ciaf185.","DOI":"10.1093\/cid\/ciaf185"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e0162322","DOI":"10.1128\/aac.01623-22","article-title":"Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e0038022","DOI":"10.1128\/aac.00380-22","article-title":"The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Flanagan, S., Walker, H., Ong, V., and Sandison, T. (2023). Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.01339-23"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e01165-19","DOI":"10.1128\/AAC.01165-19","article-title":"Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Murray, A., Cass, L., Ito, K., Pagani, N., Armstrong-James, D., Dalal, P., Reed, A., and Strong, P. (2020). PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections. J. Fungi, 6.","DOI":"10.3390\/jof6040373"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Colley, T., Sehra, G., Daly, L., Kimura, G., Nakaoki, T., Nishimoto, Y., Kizawa, Y., Strong, P., Rapeport, G., and Ito, K. (2019). Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-45890-w"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e02280-16","DOI":"10.1128\/AAC.02280-16","article-title":"In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection","volume":"61","author":"Colley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Townsend, L., and Martin-Loeches, I. (2022). Invasive Aspergillosis in the Intensive Care Unit. Diagnostics, 12.","DOI":"10.3390\/diagnostics12112712"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P. (2020). Review of the Novel Investigational Antifungal Olorofim. J. Fungi, 6.","DOI":"10.3390\/jof6030122"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/jac\/dkae267","article-title":"In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020\u20132023","volume":"79","author":"Halliday","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P. (2022). Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents. J. Fungi, 8.","DOI":"10.3390\/jof8080857"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Henig, O., and Ben-Ami, R. (2025). Antifungal Agents and Their Role in the Management of Pulmonary Aspergillosis. Pulmonary Aspergillosis: A Comprehensive Guide to the Disease Spectrum and Advances in Diagnosis and Management, Springer Nature.","DOI":"10.1007\/978-3-031-76524-7_8"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/10\/731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:37:12Z","timestamp":1760531832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/11\/10\/731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":177,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jof11100731"],"URL":"https:\/\/doi.org\/10.3390\/jof11100731","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}